Interim Results for the Six Months Ended 30 June 2024
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued...
Healthcare
Revolutionizing Surgery: SS Innovations International Inc. Celebrates 2,000 Procedures with its SSi Mantra Surgical Robotic System
FORT LAUDERDALE, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII),...
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement Paris, France, September 23, 2024, 2:00 pm CET...
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Boosted by CARES-310 Leading Overall Survival Analysis
FORT LEE, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today...
Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
Blue Cross and Blue Shield of Minnesota Launches New Center to Combat Racial and Health Inequities
Health plan focuses on evolving community needs while renewing longstanding commitment to address inequities, promote greater healthEAGAN, Minn., Sept. 23,...
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnectSAN DIEGO, Sept. 23, 2024...
MedCerts Launches Certified Cing Assistant (CNA) eLearning Program Benefiting Medical Providers, Patients and Aspiring Healthcare Professionals
New certification program features generative and conversational AI developed in-house, setting a new standard in healthcare training Program's AI-based characters...
Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to...
Therma Bright Investment Portfolio Company InStatin Secures Mountain West Research Discovery Study Agreement
Clinical research will offer insight for specific targeting of active pharmaceutical ingredients (API) that will further support Phase 1 Human...
Clarivate and Relatable Healthcare Forge Strategic Partnership to Transform Medtech Sales Contracting Process
Clarivate Medtech Intelligence and Relatable software enhance product data management and competitive conversion efficiency for medtech sales, contracting and pricing...
Hospital in Greenland chooses Sectra’s radiology solution–enhanced cross-country collaboration for improved patient care
LINKÖPING, Sweden, Sept. 23, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its enterprise...
Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development
Dublin, Ireland--(Newsfile Corp. - September 23, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is excited to announce...
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific...
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly...
Global Ultrasound Institute Launches GUSI Fellowships Platform: Elevating Point-of-Care Ultrasound Education
SAN FRANCISCO, Sept. 20, 2024 /PRNewswire/ -- The Global Ultrasound Institute (GUSI) is proud to announce the launch of the...
NuGen Announces Closing of Private Placement of $10 million Secured Convertible Debentures
Toronto, Ontario--(Newsfile Corp. - September 20, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading...
EEG and EMG Devices Market to Grow by USD 793.5 Million (2024-2028) as Rising Neurological Conditions Drive Demand, AI Impact on Market Trends – Technavio Report
NEW YORK, Sept. 20, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global EEG and EMG devices...
Global Ultrasound Institute (GUSI) Unveils POCUS Essentials Plus Simulation: A Game-Changing Advancement in Point-of-Care Ultrasound Training
Partnership with e-Sono (3B Scientific) Delivers Unmatched Learning Experience with Over 1,000 Case-Based Simulations and Comprehensive Educational Resources SAN FRANCISCO,...